The Head and Neck Cancer market size in The United States will grow at a CAGR of 8.2% by 2032

The Head and Neck Cancer Market is expected to show positive growth in the forecast period (2022-2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

Key takeaways from the Head and Neck Cancer Market Report
• In 2021, the total Head and Neck Cancer incident cases in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.
• The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distant with ~11,000 cases, and ~3,000 cases of the unknown stage.
• In 2021, the molecular alteration-specific incident cases of HNC in the US were maximum for TP53 at ~47,000 cases followed by CCND1, PIK3CA, NOTCH1, KMT2D, EGFR, NSD1, FGFR1, and HRAS mutations that had ~18,000 cases; ~14,000 cases; ~12,400 cases; ~12,000 cases; ~10,000 cases; ~6,500 cases; ~5,700 cases; and ~3,300 cases respectively.
• In 2021, the HPV status-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for HPV negative at ~40,000 cases followed by HPV positive at ~23,000 cases. By 2032, HPV status-specific incident cases of HNC are expected to increase significantly.
• Leading Head and Neck Cancer Companies such as CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others

Key benefits of the Head and Neck Cancer Market Insight Report
• Head and Neck Cancer market report covers a descriptive overview and comprehensive insight of the Head and Neck Cancer Epidemiology and Head and Neck Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• The Head and Neck Cancer market report provides insights on the current and emerging therapies.
• Head and Neck Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
• The Head and Neck Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Head and Neck Cancer market.

Know which therapies are expected to grab major Head and Neck Cancer Market Share @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Head and Neck Cancer Overview

HNC refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3-5% of all cancers in the US and are common in men and people over the age of 50. These cancers are easily preventable and can be treated if diagnosed early. The most common causes of HNC are tobacco and alcohol use, and nowadays, HPV has also emerged as an important risk factor. HNC usually begins in the squamous cells - often referred to as squamous cell carcinomas of the head and neck - that line the mucosal surfaces of the head and neck for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas.

Head and Neck Cancer Epidemiology Insights

• Head and Neck Cancer Stage-specific Incident Cases
• Head and Neck Cancer HPV-specific Incident Cases
• Total Head and Neck Cancer Incident Cases
• Head and Neck Cancer Molecular Alteration-specific Incident Cases
• Head and Neck Cancer Site-specific Incident Cases

For further information of this report to understand which factors are driving Head and Neck Cancer epidemiology trends @ https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Head and Neck Cancer Emerging Drugs

• TECENTRIQ (Atezolizumab): Hoffmann-La Roche
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• XEVINAPANT (debio 1143): Merck KGaA
• Toripalimab: Junshi Biosciences/Coherus
• Tipifarnib: Kura Oncology

Head and Neck Cancer Market Outlook

HNC is a broad indication involving many site-specific cancers, such as laryngeal and hypopharyngeal cancer, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, oral and or pharyngeal cancer, and salivary gland cancer. Many cancers of the head and neck are curable, especially if detected at an early stage. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. When planning treatment, doctors consider how treatment might affect a person's quality of life, such as how a person feels, looks, talks, eats, and breathes.

Scope of the Head and Neck Cancer Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Head and Neck Cancer Companies- CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, And many more
• Head and Neck Cancer Therapeutic Assessment- Current marketed and emerging therapies
• Head and Neck Cancer Market Dynamics- Head and Neck Cancer Market Drivers and Barriers
• Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Head and Neck Cancer Market Access and Reimbursement

Table of Content
1. Key Insights
2. Report Introduction
3. Head and Neck Cancer (HNC) -Market Overview at a Glance
4. Head and Neck Cancer (HNC) - Future Prospects
5. Executive Summary of Head and Neck Cancer
6. Key Events
7. Disease Background and Overview
8. Treatment and Management
9. Methodology
10. Head and Neck Cancer Epidemiology and Patient Population
11. Patient Journey
12. Head and Neck Cancer Marketed Products
13. Head and Neck Cancer Emerging Therapies
14. Head and Neck Cancer (HNC): Seven Major Market Analysis
15. Market Access and Reimbursement
16. KOL Views
17. SWOT Analysis
18. Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Get in touch with our Business Expert @ https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.